As such, we confirm that both S100A8/9 and S100A12 biomarker levels are useful to identify patients with pJIA who might respond well to abatacept and may help personalize JIA treatments as part of future treat-to-target strategies [3]. Here, S100A12 is linked to juvenile idiopathic arthritis.